Amgen

AMGN

Market cap $183B

New Phase 3 MITIGATE Open-Label Extension Data Support the Long-Term Safety Profile and Sustained Results of UPLIZNA ® in IgG4-RD Real-World Evidence Supports TAVNEOS ® Efficacy and Safety Profile with Reduced Steroid Use in ANCA-Associated Vasculitis THOUSAND OAKS, Calif., June 3, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data across rare autoimmune and inflammatory diseases at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, taking place from June 3-6 in London.

AMGN wins EU approval for Imdylltra in extensive-stage small cell lung cancer after phase III data showed a 40% reduction in death risk.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

THOUSAND OAKS, Calif., May 29, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:55 a.m.

Most people think you can't time the market. That's nonsense.

NVO and AMGN square off as GLP-1 leadership, pipeline depth and diversification shape a compelling healthcare stock comparison.

LOS ANGELES, May 27, 2026 /PRNewswire/ -- Ember LifeSciences, Inc., ("Ember") a leading provider of revolutionary cold chain technology, today announced strategic investments from Amgen Ventures, the corporate venture arm of Amgen (NASDAQ: AMGN ) a leading global biotechnology company and TDF Ventures, a venture capital firm focused on early-stage investments in enterprise-focused technology sectors. The investments follow Ember LifeSciences' previously announced Series A financing led by Sea Court Capital and comes as the company announces full commercial availability of the Ember Cube 2, an award-winning, reusable, modular solution designed to bring greater control and visibility to cold chain logistics through real-time monitoring and cloud-based tracking.

Amgen faces LOE headwinds and pricing pressure, yet key growth drugs and biosimilars continue gaining traction.

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Amgen delivers consistent, market-beating returns, supported by a robust growth portfolio and prudent capital allocation. AMGN's pipeline strength is evident, with 16 drugs on track for blockbuster status and promising new assets like MariTide in obesity. At a forward P/E of 15.1 and 3% yield, AMGN offers an attractive blend of income and growth, justifying a continued ‘Buy' rating.